These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 22669610)

  • 21. Botox transient treatment of tinnitus due to stapedius myoclonus: case report.
    Liu HB; Fan JP; Lin SZ; Zhao SW; Lin Z
    Clin Neurol Neurosurg; 2011 Jan; 113(1):57-8. PubMed ID: 20800344
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Botulinum toxin: clinical techniques, applications, and complications.
    Stephan S; Wang TD
    Facial Plast Surg; 2011 Dec; 27(6):529-39. PubMed ID: 22205526
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prophylactic botulinum type A toxin complex (Dysport®) for migraine without aura.
    Chankrachang S; Arayawichanont A; Poungvarin N; Nidhinandana S; Boonkongchuen P; Towanabut S; Sithinamsuwan P; Kongsaengdao S
    Headache; 2011 Jan; 51(1):52-63. PubMed ID: 21083558
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of botulinum toxin A for drug-refractory trigeminal neuralgia: preliminary report.
    Bohluli B; Motamedi MH; Bagheri SC; Bayat M; Lassemi E; Navi F; Moharamnejad N
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2011 Jan; 111(1):47-50. PubMed ID: 20674409
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of botulinum toxin A for treatment of myofascial pain and dysfunction.
    Fallah HM; Currimbhoy S
    J Oral Maxillofac Surg; 2012 May; 70(5):1243-5. PubMed ID: 22538024
    [No Abstract]   [Full Text] [Related]  

  • 26. Study of botulinum toxin A in neurogenic bladder due to spina bifida in children.
    Deshpande AV; Sampang R; Smith GH
    ANZ J Surg; 2010 Apr; 80(4):250-3. PubMed ID: 20575951
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Botulinum toxin type A in the treatment of Raynaud's phenomenon.
    Neumeister MW
    J Hand Surg Am; 2010 Dec; 35(12):2085-92. PubMed ID: 21134617
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical use of botulinum toxins in oral and maxillofacial surgery.
    Majid OW
    Int J Oral Maxillofac Surg; 2010 Mar; 39(3):197-207. PubMed ID: 19959337
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Botulinum toxin type A in the treatment of facial myotonia in Schwartz-Jampel syndrome.
    Bandeira ID; Jagersbacher JG; Barretto TL; Santos CV; Lucena R
    Muscle Nerve; 2017 Aug; 56(2):E10-E11. PubMed ID: 28187499
    [No Abstract]   [Full Text] [Related]  

  • 30. Treatment of compensatory hyperhidrosis with botulinum toxin type A.
    Belin EE; Polo J
    Cutis; 2003 Jan; 71(1):68-70. PubMed ID: 12553633
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Botulinum toxin type A for neuropathic itch.
    Wallengren J; Bartosik J
    Br J Dermatol; 2010 Aug; 163(2):424-6. PubMed ID: 20346021
    [No Abstract]   [Full Text] [Related]  

  • 32. [Efficacy and safety of botulinum toxin in the treatment of sialorrhea in children with neurological disorders].
    García Ron A; Miranda MC; Garriga Braun C; Jensen Verón J; Torrens Martinez J; Diez Hanbino MP
    An Pediatr (Barc); 2012 Oct; 77(4):289-91. PubMed ID: 22652186
    [No Abstract]   [Full Text] [Related]  

  • 33. The lesion causing continuous facial myokymia in multiple sclerosis.
    Jacobs L; Kaba S; Pullicino P
    Arch Neurol; 1994 Nov; 51(11):1115-9. PubMed ID: 7980106
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Botulinum toxin to minimize facial scarring.
    Jablonka EM; Sherris DA; Gassner HG
    Facial Plast Surg; 2012 Oct; 28(5):525-35. PubMed ID: 23027220
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relief by botulinum toxin of voiding dysfunction due to prostatitis.
    Maria G; Destito A; Lacquaniti S; Bentivoglio AR; Brisinda G; Albanese A
    Lancet; 1998 Aug; 352(9128):625. PubMed ID: 9746032
    [No Abstract]   [Full Text] [Related]  

  • 36. Botulinum toxin type A for Levodopa-induced cervical dyskinesias in Parkinson's disease: unfavorable risk-benefit ratio.
    Espay AJ; Vaughan JE; Shukla R; Gartner M; Sahay A; Revilla FJ; Duker AP
    Mov Disord; 2011 Apr; 26(5):913-4. PubMed ID: 21432906
    [No Abstract]   [Full Text] [Related]  

  • 37. Inverse psoriasis and hyperhidrosis of the axillae responding to botulinum toxin type A.
    Saber M; Brassard D; Benohanian A
    Arch Dermatol; 2011 May; 147(5):629-30. PubMed ID: 21576592
    [No Abstract]   [Full Text] [Related]  

  • 38. Discussion: quantitative measurement of evolution of postparetic ocular synkinesis treated with botulinum toxin type A.
    Salles AG
    Plast Reconstr Surg; 2013 Nov; 132(5):1265-1267. PubMed ID: 24165607
    [No Abstract]   [Full Text] [Related]  

  • 39. Botulinum toxin type A for the treatment of postamputation residual limb myokymia: a case report.
    Dave SJ; Salyer J; Desai KA
    PM R; 2010 Aug; 2(8):777-9. PubMed ID: 20709306
    [No Abstract]   [Full Text] [Related]  

  • 40. Botulinum toxin for the treatment of early-onset esotropia in children with cerebral palsy.
    Petrushkin H; Oyewole K; Jain S
    J Pediatr Ophthalmol Strabismus; 2012; 49(2):125. PubMed ID: 22420914
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.